TAMOXIFEN REDUCES BREAST CANCER RISK - FDA PANEL

It was unclear if Tamoxifen, an existing breast cancer treatment made
by British-based Zeneca Group Plc, had any benefit beyond the five
years it was studied. The drug might have risks that overshadow its
benefits in the long term, the committee said.

``As yet, there is not compelling evidence for prevention,'' said
Richard Schilsky of the University of Chicago Medical Center. ``There
is compelling evidence for reduction of short-term incidence of breast
cancer.''

The FDA generally follows its panel's advice. That means the drug, on
a fast-track review, could receive the agency's backing within months.

Data released in April from one of the largest cancer prevention
studies ever showed that tamoxifen almost halved the chance of getting
breast cancer in healthy women who had many risk factors, such as a
family history of the disease. But it is unclear whether tamoxifen can
be taken safely for long periods.

Checked-by: Patrick Henry